Investing.com -- Bank of America upgraded Moderna to Neutral with a $170 price objective, following a sharp rally in the stock after positive data on its personalized cancer vaccine, intismeran, in adjuvant melanoma.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
131last 24h
863last 7d
142● bullish (7d)
99● bearish (7d)
214publishers
Investing.com35d agobullish
BofA upgrades Moderna after 177% rally driven by cancer vaccine breakthroughGuruFocus.com37d agobearish
Intel Stock Plunges 7% as UBS Cuts Price Target to $112Intel Stock Takes Another Hit as UBS Trims Price Target to $112